All Clinical Trials in Canada

A listing of 3905 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

Canada

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

NCT06091254

Recruiting

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone. The aim of Part 2 of the study is to see how the study drug works compared... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: University of Arizona Cancer Center, Tucson, Arizona +186 locations

University of Arizona Cancer Center, Tucson, Arizona

David Geffen School of Medicine at UCLA, Los Angeles, California

UC Irvine Health, Orange, California

Investigative Clinical Research of Indiana, Noblesville, Indiana

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Hattiesburg Clinic, Hattiesburg, Mississippi

Icahn School of Medicine at Mt Sinai, New York, New York

Stony Brook University Hospital, Stony Brook, New York

Clinical Research Alliance Inc, Westbury, New York

University of North Carolina, Chapel Hill, North Carolina

Levine Cancer Institute, Charlotte, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Vanderbilt University Medical Center, Nashville, Tennessee

Center for Oncology and Blood Disorders, Houston, Texas

HOPE Cancer Center of East Texas, Tyler, Texas

Huntsman Cancer Institute - Oncology Division, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Virginia Commonwealth University, Richmond, Virginia

Prohealth Care Inc, Waukesha, Wisconsin

Ingham Institute, Liverpool, New South Wales

Icon Cancer Centre - Wesley, Auchenflower, Queensland

Flinders Medical Centre, Bedford Park, South Australia

Monash Health, Clayton, Victoria

Epworth Freemasons, East Melbourne, Victoria

St Vincent's Hospital - Melbourne, Fitzroy, Victoria

Alfred Hospital and Monash University, Melbourne, Victoria

Ordensklinikum Linz, Linz, Osterreich

Ordensklinikum Linz Gmbh, Elisabethinen, Linz, Not set

Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III, Salzburg, Not set

Medical University of Vienna, Vienna, Not set

Hanusch Krankenhaus, Vienna, Not set

AZ St.-Elisabeth Herentals vzw, Herentals, Antwerp

Hopital De Jolimont, Haine-Saint-Paul, Hainaut

Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital, Gent, Oost-Vlaanderen

Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Not set

Institut Jules Bordet, Brussels, Not set

Ensino e Terapia de Inovacao Clinica Amo (Etica), Salvador, Bahia

Instituto Mario Pena de Ensino Pesquisa e Inovacao, Belo Horizonte, Minas Gerais

Liga Norte Riograndense Contra o Cancer, Natal, Rio Grande Do Norte

Instituto do Cancer em Hospital Sao Vicente de Paulo, Passo Fundo, Rio Grande Do Sul

Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul

Centro de Hematologia e Oncologia, Joinville, Santa Catarina

Animi Unidade de Tratamento Oncologico Ltda, Lages, Santa Catarina

Fundacao Pio XII Hospital de Amor, Barretos, Sao Paulo

Amaral Carvalho Hospital, Jau, Sao Paulo

Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirao Preto, Sao Paulo

Instituto DOr de Pesquisa e Ensino Df Star, Brasilia, Not set

Instituto Nacional de Cancer Jose Alencar Gomes da Silva, Rio de Janeiro, Not set

Instituto Americas, Rio de Janeiro, Not set

Hospital Alemao Oswaldo Cruz, Sao Paulo, Not set

AC Camargo Cancer Center, Sao Paulo, Not set

Clinical Hospital of Medicine School at Sao Paulo University, Sao Paulo, Not set

Casa de Saude Santa Marcelina, Sao Paulo, Not set

Tom Baker Cancer Center, Calgary, Alberta

Saint John Regional Hospital, Saint John, New Brunswick

Cisss de la Monteregie-Centre, Greenfield Park, Quebec

CHU de Quebec - Universite Laval, Quebec City, Quebec

Ciusss de Lestrie - Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec

Fundacion Arturo Lopez Perez, Santiago, Region Metropolitana

Inmunocel, Santiago, Region Metropolitana

Clinica Alemana de Santiago, Santiago, Region Metropolitana

Centro Oncologia de Precision Universidad Mayor, Santiago, Not set

University Hospital Hradec Kralove, Hradec Kralove, Not set

University Hospital Kralovske Vinohrady, Prague, Not set

Vseobecna Fakultni Nemocnice, Praha, Not set

Centre Hospitalier Universitaire (CHU) Rennes, Rennes, Bretagne

Centre Hospitalier Regional Universitaire de Tours, Tours, Centre Val De Loire

Hopital Victor Dupouy Argenteuil, Argenteuil, Ile De France

Gustave Roussy, Villejuif, Ile De France

Nantes University Hospital, Nantes, Pays De La Loire

Hopital de la Conception, Marseille, Provence-Alpes-Cote d'Azur

Centre Hospitalier Universitaire Angers, Angers, Not set

Institut Paoli Calmettes, Marseille, Not set

Hopital Saint Louis, Paris, Not set

Hopital Saint-Antoine, Paris, Not set

Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, Not set

Institut de Cancerologie Strasbourg Europe (ICANS), Strasbourg, Not set

University Hospital Wurzburg, Würzburg, Bavaria

Kliniken Ostalb Stauferklinikum Schwab Gmund, Mutlangen, Gmund

Clinic Frankfurt (Oder), Frankfurt, Hesse

Universitatsmedizin der Johannes-Gutenberg Universitat Mainz, Mainz, Rheinland-Pfalz

Hematological Praxis Dresden, Dresden, Sachsen

Charite Universitatsmedizin Berlin Campus Benjamin Franklin, Berlin, Not set

University Hospital Carl Gustav Carus, Dresden, Not set

Stadtisches Krankenhaus Kiel, Kiel, Not set

Samson Assuta Ashdod University Hospital, Ashdod, Not set

Bnai Zion Medical Center, Haifa, Not set

Hadassah Medical Center, Jerusalem, Not set

Galilee Medical Center, Nahariya, Not set

Rabin Medical Center, Petah-Tikva, Not set

Chaim Sheba Medical Center, Ramat-Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Istituto Romagnolo Per Lo Studio Dei Tumori, Meldola, Forli Cesena

Irccs Aou Di Bologna- Policlinico Di Sant'Orsola Malpighi, Bologna, Italia

Pia Fondazione Panico, Tricase, Lecce

IRCCS Ospedale Policlinico San Martino, Genoa, Liguria

Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Torino

UOC Ematologia e Terapia Cellulare - PO Mazzoni AST Ascoli Piceno, Ascoli Piceno, Not set

Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Not set

Istituto Europeo di Oncologia, Milano, Not set

Federico II University, Napoli, Not set

AOU Maggiore della Carita-SCDU Ematologia, Novara, Not set

UO Ematologia Ravenna, Ravenna, Not set

Santa Maria della Misericordia, Udine, Not set

Ospedale dell'Angelo - Varese, Varese, Not set

Center for Hematologic Malignancy, Goyang, Gyeonggi-do

St. Vincents Hospital - The Catholic University of Korea, Suwon-si, Gyeonggi-do

Ajou University Hospital, Suwon-si, Gyeonggi-do

Dong-A University Hospital, Busan, Not set

Pusan National University Hospital, Busan, Not set

Jeonbuk National University Hospital, Jeonju, Not set

Seoul St. Mary's Hospital, Seoul, Not set

Uniwersytecki Szpital Kliniczny, Wroclaw, Dolnoslaskie

Specjalistyczny Szpital im A. Sokolowskiego w Walbrzychu, Walbrzych, Lower Silesian

Pratia MCM Krakow, Krakow, Malopolska

Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie

Cm Pratia Poznan, Skorzewo Poznan, Wielkopolska

Aidport, Skorzewo, Wielkopolska

Pratia Onkologia Katowice, Katowice, Not set

Copernicus Memorial Hospital, Lodz, Not set

Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Not set

Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa, Warszawa, Not set

University Hospital of Santiago de Compostela, Santiago de Compostela, A Coruna

Hospital Universitario Virgen De La Victoria Malaga, Malaga, Andalucia

Hospital Universitario Virgen Macarena, Sevilla, Andalucia

Hospital Universitario Central De Asturias, Oviedo, Asturias

Son Espases University Hospital, Palma, Balearic Islands

Cruces University Hospital (Hospital Universitario Cruces), Barakaldo, Bizkaia

Hospital Universitario Marques de Valdecilla, Santander, Cantabria

Complejo Hospitalario Universitario de a Coruna, A Coruna, Galicia

Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid

Hospital Clinico Universitario Virgen De La Arrixaca, El Palmar, Murcia

Hospital Universitario de Navarra, Pamplona, Navarra

University Hospital Vall d'Hebron, Barcelona, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital Virgen De Las Nieves De Granada, Granada, Not set

Gregorio Maranon, Madrid, Not set

Clinica Universidad de Navarra, Madrid, Not set

Fundacion Jimenez Diaz University Hospital, Madrid, Not set

University Hospital & Research Institute, Madrid, Not set

Hospital Universitario HM Sanchinarro, Servicio de Hematologia, Madrid, Not set

Morales Meseguer Hospital, Murcia, Not set

Complexo Hospitalario Universitario de Ourense, Ourense, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Virgen de Valme, Sevilla, Not set

University Hospital Virgen del Rocio, Seville, Not set

Hospital General Universitario de Toledo, Toledo, Not set

Hospital Clinico Universitario Valencia, Valencia, Not set

Hospital Universitari and Politecnic La Fe, Valencia, Not set

Hospital Clinico Lozano Blesa, Zaragoza, Not set

Kantonsspital Baden, Baden, Aargau

Cantonal Hospital St Gallen, St Gallen, Saint Gallen

Kantonsspital Winterthur Medical Oncology, Winterthur, Schweiz

University Hospital Basel, Basel, Not set

Inselspital Bern University Hospital, Bern, Not set

Chang Gung Medical Foundation Chia Yi Branch, Puzi City, Chiayi County

Chang Gung Memorial Hospital Linkou, Taoyuan City, Guishan District

Changhua Christian Hospital, Changhua City, Not set

Chung-Ho Memorial Hospital, Kaohsiung, Not set

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set

Taipei Medical University-Shuang Ho Hospital, New Taipei City, Not set

Taichung General Veterans Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

Tri-Service General Hospital, Taipei City, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Taipei Municipal Wan Fang Hospital, Taipei, Not set

Ankara University Faculty of Medicine, Mamak, Ankara

Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Yenimahalle, Ankara

Gazi University, Ankara, Central Anatolia

VM Medical Park Mersin Hospital, Mezitli, Mersin

Tekirdag Namik Kemal University Hospital, Tekirdag, Suleymanpasa

Liv Hospital Ankara, Ankara, Not set

VKV American Hopital, Istanbul, Not set

Istanbul University Istanbul Faculty of Medicine, Istanbul, Not set

Ege University, Izmir, Not set

Erci̇yes Uni̇versi̇ty, Kayseri, Not set

Sakarya University Medical Faculty, Sakarya, Not set

Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi, Samsun, Not set

Zonguldak Bulent Ecevit University, Zonguldak, Not set

Royal Cornwall Hospital NHS Trust, Truro, Cornwall

Derriford Hospital and the Royal Eye Infirmary, Plymouth, Devon

University Hospitals Dorset, Bournemouth, Dorset

Beatson West of Scotland Cancer Centre, Glasgow, Lanarkshire

Norfolk and Norwich University Hospital, Norwich, Norfolk

Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, Not set

Conditions: Follicular Lymphoma (FL)

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Recruiting

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: Bass Medical Group ( Site 0166), Walnut Creek, California +108 locations

Bass Medical Group ( Site 0166), Walnut Creek, California

Innovative Clinical Research Institute ( Site 0122), Whittier, California

Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida

Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky

University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky

Louisiana State University Health Sciences Center New Orleans ( Site 0134), New Orleans, Louisiana

University of Maryland ( Site 0123), Baltimore, Maryland

Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts

University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts

St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana

Atlantic Health System ( Site 0116), Morristown, New Jersey

New York Medical College ( Site 0113), Valhalla, New York

Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee

Hospital Italiano de Buenos Aires ( Site 2203), Ciudad Autonoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205), Mar del Plata., Buenos Aires

Hospital Aleman ( Site 2200), Buenos Aites, Caba

Instituto Alexander Fleming ( Site 2201), Caba, Not set

Hospital Privado Universitario de Córdoba ( Site 2202), Cordoba, Not set

Townsville University Hospital ( Site 1800), Douglas, Queensland

Grampians Health ( Site 1802), Ballarat, Victoria

Royal Perth Hospital-Haematology ( Site 1801), Perth, Western Australia

Hospital Erasto Gaertner ( Site 2302), Curitiba, Parana

Liga Norte Riograndense Contra o Câncer ( Site 2305), Natal, Rio Grande Do Norte

Hospital Paulistano ( Site 2300), Sao Paulo, Not set

Pesquisa Clínica do Serviço de Hematologia do Hospital das Clínicas da FMUSP ( Site 2306), Sao Paulo, Not set

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Biocenter ( Site 2401), Concepcion., Biobio

IC La Serena Research ( Site 2405), La Serena, Coquimbo

Oncocentro Valdivia ( Site 2407), Valdivia., Los Rios

FALP-UIDO ( Site 2400), Santiago., Region M. De Santiago

Clínica Inmunocel ( Site 2404), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 2409), Santiago, Region M. De Santiago

Bradfordhill ( Site 2403), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 3000), Beijing, Beijing

Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing, Chongqing

Chongqing University Three Gorges Hospital ( Site 3026), Chongqing, Chongqing

Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou, Guangdong

Zhujiang Hospital ( Site 3002), Guangzhou, Guangdong

The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan

Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan, Hubei

The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang, Jiangxi

The First Hospital of Jilin University-Hematology ( Site 3012), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 3009), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Cheng Du, Sichuan

Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu, Sichuan

Zhejiang Cancer Hospital ( Site 3014), Hangzhou, Zhejiang

The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027), Hangzhou, Zhejiang

Hospital Pablo Tobon Uribe ( Site 0804), Medellin, Antioquia

Instituto Médico de Alta Tecnologia S.A.S ( Site 0803), Monteria, Cordoba

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801), Bogota, Distrito Capital De Bogota

Oncologos del Occidente ( Site 0800), Pereira., Risaralda

Fundacion Valle del Lili ( Site 0802), Cali, Valle Del Cauca

Hospital Metropolitano - Sede Lindora ( Site 2500), Santa Ana, San Jose

CIMCA ( Site 2501), San Jose, Not set

centre hospitalier lyon sud-Service Hématologie ( Site 0702), Pierre-Bénite, Rhone

Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700), Paris, Not set

University Hospital of Alexandroupolis ( Site 0903), Alexandroupolis, Anatoliki Makedonia Kai Thraki

Evangelismos General Hospital of Athens ( Site 0900), Athens, Attiki

Regional General Hospital of Athens "Laiko" ( Site 0901), Athens, Attiki

MEDI-K ( Site 2602), Guatemala, Not set

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601), Guatemala, Not set

CELAN,S.A ( Site 2603), Guatemala, Not set

Queen Mary Hospital ( Site 3100), Hong Kong, Not set

Princess Margaret Hospital ( Site 3101), Hong Kong, Not set

Emek Medical Center-Hematology Unit ( Site 1102), Afula, Not set

Carmel Hospital ( Site 1103), Haifa, Not set

Hadassah Medical Center ( Site 1100), Jerusalem, Not set

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203), Rozzano, Milano

IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200), Bologna, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202), Napoli, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204), Roma, Not set

Seoul National University Hospital-Oncology ( Site 0302), Seoul, Not set

Samsung Medical Center ( Site 0300), Seoul, Not set

Health Pharma Professional Research S.A. de C.V: ( Site 2700), Ciudad de Mexico, Distrito Federal

Medivest Centro de Investigación Integral ( Site 2704), Chihuahua, Not set

Centro de Infusion Superare ( Site 2701), Mexico City, Not set

Aotearoa Clinical Trials ( Site 0501), Auckland, Not set

Clínicas AUNA Sede Chiclayo ( Site 2803), Chiclayo, Lambayeque

Clínica San Felipe ( Site 2805), Lima, Not set

Hospital Nacional Edgardo Rebagliati Martins ( Site 2802), Lima, Not set

Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 1305), Walbrzych, Dolnoslaskie

Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301), Wroclaw, Dolnoslaskie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1303), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300), Warszawa, Mazowieckie

Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302), Gdynia, Pomorskie

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309), Słupsk, Pomorskie

Pratia Onkologia Katowice ( Site 1306), Katowice, Slaskie

Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400), Bangkok, Krung Thep Maha Nakhon

Chulalongkorn University ( Site 0402), Pathumwan, Krung Thep Maha Nakhon

Maharaj Nakorn Chiang Mai Hospital ( Site 0401), Chiang Mai, Not set

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912), Yenimahalle, Ankara

Ege University Medicine of Faculty ( Site 1902), Bornova, Izmir

Ankara University Hospital Cebeci-hematology ( Site 1901), Ankara, Not set

Mega Medipol-Hematology ( Site 1909), Istanbul, Not set

Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Not set

Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Not set

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000), Cherkasy, Cherkaska Oblast

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004), Ivano-Frankivsk, Ivano-Frankivska Oblast

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002), Lviv, Lvivska Oblast

State non-profit enterprise National Cancer Institute ( Site 2001), Kyiv, Not set

National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005), Kyiv, Not set

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2003), Kyiv, Not set

Aberdeen Royal Infirmary ( Site 2104), Aberdeen, Aberdeen City

The Royal Cornwall Hospital ( Site 2103), Truro, England

University College London Hospital-Cancer Clinical Trials Unit ( Site 2100), London-Camden, London, City Of

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma

Learn More ›

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103

Recruiting

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Gender:

ALL

Ages:

Between 6 months and 25 years

Trial Updated:

07/18/2025

Locations: Children's Hospital Los Angeles ( Site 1006), Los Angeles, California +56 locations

Children's Hospital Los Angeles ( Site 1006), Los Angeles, California

Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado

Yale-New Haven Hospital ( Site 1012), New Haven, Connecticut

Johns Hopkins All Children's Hospital ( Site 1025), Saint Petersburg, Florida

University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City, Iowa

Dana-Farber Cancer Institute ( Site 1013), Boston, Massachusetts

Corewell Health ( Site 1001), Grand Rapids, Michigan

Children's Mercy Hospital ( Site 1024), Kansas City, Missouri

Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick, New Jersey

New York Medical College ( Site 1023), Valhalla, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota

Oregon Health and Science University ( Site 1004), Portland, Oregon

Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania

Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls, South Dakota

University of Texas MD Anderson Cancer Center ( Site 1007), Houston, Texas

Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City, Utah

Sydney Children's Hospital-Kids Cancer Centre ( Site 1997), Randwick, New South Wales

Queensland Children's Hospital-Oncology & Haematology ( Site 1996), Brisbane, Queensland

UZ Gent ( Site 1428), Gent, Oost-Vlaanderen

Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268), Curitiba, Parana

Hospital de Clinicas de Porto Alegre ( Site 1265), Porto Alegre, Rio Grande Do Sul

Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264), Barretos, Sao Paulo

Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1267), São José do Rio Preto, Sao Paulo

McGill University Health Centre-Pediatric HematologyOncology ( Site 1223), Montréal, Quebec

Hospital Carlos Van Buren ( Site 1880), Valparaíso, Valparaiso

Hospital Pablo Tobon Uribe ( Site 1923), Medellin, Antioquia

Clinica de la Costa S.A.S.-Clinical Research Oncology & Hematology -Pediatric ( Site 1924), Barranquilla, Atlantico

IMAT S.A.S ( Site 1921), Monteria, Cordoba

Rigshospitalet-Department of paediatrics and adolescent medicine, Section of Paed haem-onc ( Site 1467), Copenhagen, Hovedstaden

CHU de Bordeaux. Hopital Pellegrin ( Site 1105), Bordeaux, Aquitaine

Gustave Roussy ( Site 1103), Villejuif, Ile-de-France

Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1104), Nantes, Pays-de-la-Loire

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 1102), Marseille, Provence-Alpes-Cote-d Azur

CENTRE LEON BERARD-IHOPE (pediatrric oncology) ( Site 1100), Lyon, Rhone-Alpes

Universitätsklinikum Münster - Albert Schweitzer Campus-Pädiatrische Hämatologie und Onkologie ( Site 1141), Münster, Nordrhein-Westfalen

Aghia Sophia Children's Hospital-First Department of Pediatrics, National and Kapodistrian Universi ( Site 1797), Athens, Attiki

Semmelweis Egyetem ( Site 1838), Budapest, Not set

Rambam Health Care Campus-Pediatric Hemato-Oncology ( Site 1674), Haifa, Not set

Sheba Medical Center ( Site 1675), Ramat Gan, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori-Pediatric Oncology ( Site 1552), Milan, Lombardia

Ospedale Pediatrico Bambino Gesù IRCCS-Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica ( Site 1553), Rome, Roma

Seoul National University Hospital-Pediatrics ( Site 1972), Seoul, Not set

Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 1973), Seoul, Not set

Prinses Maxima Centrum voor Kinderoncologie ( Site 1510), Utrecht, Not set

Narodny ustav detskych chorob ( Site 1592), Bratislava, Bratislavsky Kraj

Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 1717), Esplugas De Llobregat, Barcelona

Hospital Infantil Universitario Niño Jesús-Servicio de Onco-Hematología Pediátrica ( Site 1715), Madrid, Madrid, Comunidad De

Hospital Universitari Vall d'Hebron-Servei de Hematologia i Oncologia Pediatrica ( Site 1716), Barcelona, Not set

Prövningsenhet barn, Sahlgrenska Universitetssjukhuset ( Site 1634), Gothenburg, Vastra Gotalands Lan

National Taiwan University Hospital ( Site 1983), Taipei, Not set

Hacettepe Universite Hastaneleri ( Site 1961), Ankara, Not set

Ankara Bilkent Şehir Hastanesi ( Site 1962), Ankara, Not set

Ege Universitesi Hastanesi ( Site 1963), İzmir, Not set

Royal Victoria Infirmary-Great North Children's Hospital ( Site 1348), Newcastle upon Tyne, England

University College London Hospital ( Site 1350), London, London, City Of

Royal Marsden Hospital (Sutton)-Drug Development Unit ( Site 1347), Sutton., Surrey

University Hospital of Wales ( Site 1346), Cardiff, Not set

Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma

Learn More ›

MagDI Canada Study

NCT06467955

Recruiting

The objective of the MagDI Canada study is to evaluate the performance and safety of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion as one example of a small bowel clinical procedure requiring a side-to-side anastomosis. The secondary objective includes initial efficacy of the duodeno-ileal diversion using the MagDI System.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/18/2025

Locations: University of Toronto, Toronto, Ontario +2 locations

Conditions: Obesity, Type 2 Diabetes

Learn More ›

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310

Recruiting

A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE

Gender:

ALL

Ages:

Between 5 years and 17 years

Trial Updated:

07/18/2025

Locations: Research Site, Phoenix, Arizona +91 locations

Research Site, Phoenix, Arizona

Research Site, Los Angeles, California

Research Site, Washington, District of Columbia

Research Site, Chicago, Illinois

Research Site, Bethesda, Maryland

Research Site, Saint Paul, Minnesota

Research Site, Bronx, New York

Research Site, New Hyde Park, New York

Research Site, New York, New York

Research Site, Valhalla, New York

Research Site, Durham, North Carolina

Research Site, Cincinnati, Ohio

Research Site, Cleveland, Ohio

Research Site, Columbus, Ohio

Research Site, Portland, Oregon

Research Site, Philadelphia, Pennsylvania

Research Site, Greenville, South Carolina

Research Site, El Paso, Texas

Research Site, Houston, Texas

Research Site, Salt Lake City, Utah

Research Site, Buenos Aires, Not set

Research Site, Córdoba, Not set

Research Site, Rosario, Not set

Research Site, Botucatu, Not set

Research Site, Curitiba, Not set

Research Site, Porto Alegre, Not set

Research Site, Ribeirão Preto, Not set

Research Site, Sao Paulo, Not set

Research Site, São Paulo, Not set

Research Site, Vancouver, British Columbia

Research Site, Toronto, Ontario

Research Site, Beijing, Not set

Research Site, Changchun, Not set

Research Site, Changsha, Not set

Research Site, Shanghai, Not set

Research Site, Suzhou, Not set

Research Site, Wenzhou, Not set

Research Site, Zhengzhou, Not set

Research Site, Barranquilla, Not set

Research Site, Medellin, Not set

Research Site, Bordeaux, Not set

Research Site, Bron, Not set

Research Site, Le Kremlin-Bicêtre, Not set

Research Site, LILLE Cedex, Not set

Research Site, Toulouse, Not set

Research Site, Berlin, Not set

Research Site, Freiburg, Not set

Research Site, Sankt Augustin, Not set

Research Site, Genova, Not set

Research Site, Milano, Not set

Research Site, Padova, Not set

Research Site, Roma, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Chiba, Not set

Research Site, Fuchu-shi, Not set

Research Site, Kawasaki-shi, Not set

Research Site, Kobe-shi, Not set

Research Site, Obu-shi, Not set

Research Site, Shinjuku-ku, Not set

Research Site, Yokohama-shi, Not set

Research Site, Guadalajara, Not set

Research Site, Merida, Not set

Research Site, Mexico, Not set

Research Site, Monterrey, Not set

Research Site, Toluca, Not set

Research Site, Lodź, Not set

Research Site, Warszawa, Not set

Research Site, Wroclaw, Not set

Research Site, Lisboa, Not set

Research Site, Porto, Not set

Research Site, Cape Town, Not set

Research Site, Esplugues de Llobregat, Not set

Research Site, Madrid, Not set

Research Site, Málaga, Not set

Research Site, Valencia, Not set

Research Site, Ankara, Not set

Research Site, İstanbul, Not set

Research Site, Kayseri, Not set

Research Site, Umraniye, Not set

Research Site, Birmingham, Not set

Research Site, Bristol, Not set

Research Site, Liverpool, Not set

Research Site, London, Not set

Research Site, Manchester, Not set

Research Site, Southampton, Not set

Conditions: Systemic Lupus Erythematosus

Learn More ›

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515

Recruiting

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: City of Hope, Duarte, California +51 locations

City of Hope, Duarte, California

University of California, Los Angeles (UCLA), Los Angeles, California

Sarah Cannon Research Institute at HealthOne, Denver, Colorado

Sibley Memorial Hospital, Washington, District of Columbia

Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando, Florida

Emory University School of Medicine, Atlanta, Georgia

Community Health Network, Indianapolis, Indiana

Massachusetts General Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan

New York University (NYU) Langone Medical Center, New York, New York

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York

Duke University Medical Center, Durham, North Carolina

University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

USO - US Oncology Research Network, Nashville, Tennessee

Vanderbilt University School of Medicine, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

South Texas Accelerated Research Therapeutics (START), San Antonio, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Fred Hutchinson Cancer Center, Seattle, Washington

University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin

The Ottawa Hospital, Ottawa, Ontario

Princess Margaret Hospital, Toronto, Ontario

Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Not set

Beijing Cancer hospital, Beijing, Not set

Harbin Medical University Cancer Hospita, Harbin, Not set

Fudan University Cancer Center, Shanghai, Not set

Centre Leon Berard, Lyon, Not set

Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM) - AP-HM Hopital de La Timone, Marseille, Not set

Oncopole Claudius Regaud, Toulouse, Not set

Institut Gustave Roussy, Villejuif cedex, Not set

Charite Universitaetsmedizin Berlin, Berlin, Not set

Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Not set

Universitaetsklinikum Essen, Essen, Not set

Klinikum der Ludwig-Maximilians-Universitaet Muenchen, Munchen, Not set

START Dublin Early Phase Clinical Trials Unit, Dublin, Not set

Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Not set

UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Not set

Centro Ricerche Cliniche di Verona s.r.l., Verona, Not set

Kanagawa cancer center, Kanagawa, Not set

National Cancer Center Hospital East, Kashiwa, Chiba, Not set

Aichi Cancer Center Hospital, Nagoya, Not set

Kansai Medical University Hospital, Osaka, Not set

National Cancer Center Hospital, Tokyo, Not set

South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos, Barcelona, Not set

Hospital Universitario Vall d'Hebron, Barcelona, Not set

South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

Learn More ›

Feasibility and Acceptability of an Evidence-Informed Virtual Intervention to Reduce Perceptions of Injustice Following Work Injury

NCT07072702

Recruiting

Many individuals who have sustained disabling injuries in the workplace react to their situation with a sense of 'injustice'. Research over the past 20 years has revealed that, interpreting one's post-injury life situation as 'unjust', actually interferes with recovery from the disabling injury. Post-injury perceptions of injustice contribute to more severe pain, more severe symptoms of depression and PTSD, and more prolonged absence from work. Several clinical researchers have highlighted the need to develop approaches to treatment that can reduce post-injury perceptions of injustice. A brief intervention was developed to reduce post-injury perceptions of injustice. The intervention consists of 4 30-minute sessions with a psychologist. The intervention is called 'Managing Post-Injury Challenges' (MPIC). The MPIC sessions are delivered virtually (online). As a first step toward determining whether MPIC has added value for promoting more successful recovery following work injury, the proposed research will assess the feasibility of MPIC. Some of the feasibility questions that will be addressed include: Are injured workers interested in participating in MPIC? Do injured individuals remain sufficiently engaged to complete all 4 sessions of MPIC? Does participation in MPIC contribute to meaningful reductions in perceived injustice? And are injured individuals satisfied with the benefits of MPIC? MPIC differs from many other rehabilitation interventions in that it focuses on a 'risk-factor' for problematic recovery as opposed to treating a specific health or mental health problem. At this time, there is little information about whether injured workers are interested in interventions focusing on 'risk factors' for problematic recovery. As a first step in evaluating the effectiveness of MPIC, it is necessary to demonstrate that MPIC is acceptable to injured workers. We would consider the study to be successful if 1) at least 75% of eligible injured workers agree to enrol in MPIC, 2) if at least 75% of participants attend all 4 sessions of MPIC, and if at least 75% of participants are satisfied with the benefits they derived from their involvement in MPIC. If MPIC is ultimately shown to be effective in reducing post-injury perceptions of injustice, offering MPIC to injured workers with elevated scores on a measure of perceived injustice could contribute to more successful recovery. Read Less

Gender:

ALL

Ages:

Between 25 years and 65 years

Trial Updated:

07/17/2025

Locations: McGill University, Montreal, Quebec

Conditions: MSK Conditions

Learn More ›

PulseSelect™ PFA Global Registry

NCT06393920

Recruiting

The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: Vancouver General Hospital, Vancouver, British Columbia +14 locations

Conditions: Atrial Fibrillation

Learn More ›

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280

Recruiting

The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: Kaiser Permanente Bonita Medical Offices, Bonita, California +80 locations

Kaiser Permanente Bonita Medical Offices, Bonita, California

AMCR Institute, Escondido, California

Mary & Dick Allen Diabetes Center, Newport Beach, California

University Clinical Investigators, Inc., Tustin, California

University of Colorado Anschutz Medical Campus, Aurora, Colorado

Metabolic Research Institute, Inc., West Palm Beach, Florida

Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa

HealthPartners Institute dba International Diabetes Center, Minneapolis, Minnesota

Clinical Research Professionals, Chesterfield, Missouri

Clinvest Headlands Llc, Springfield, Missouri

Las Vegas Endocrinology, Henderson, Nevada

University of North Carolina Medical Center, Chapel Hill, North Carolina

Velocity Clinical Research, Dallas, Dallas, Texas

Juno Research, Houston, Texas

Southern Endocrinology Associates, Mesquite, Texas

Texas Diabetes & Endocrinology, P.A., Round Rock, Texas

San Antonio Clinical Trials, San Antonio, Texas

Texas Valley Clinical Research, Weslaco, Texas

Stat Research S.A., Buenos Aires, Ciudad Autónoma De Buenos Aires

Mautalen Salud e Investigación, Buenos Aires, Ciudad Autónoma De Buenos Aires

CIPADI - Centro Integral de Prevencion y Atencion en Diabetes, Godoy Cruz, Mendoza

Centro de Investigaciones Clínicas Baigorria, Granadero Baigorria, Santa Fe

Instituto Médico Catamarca IMEC, Rosario, Santa Fe

Investigaciones Clínicas Tucumán, San Miguel de Tucuman, Tucumán

Buenos Aires Macula S.A, Buenos Aires, Not set

Centro Diabetológico Dr. Waitman, Córdoba, Not set

Instituto de Estudos e Pesquisas Clinicas do Ceara IEP-CE, Fortaleza, Ceará

Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal

Cendi - Endocrinologia e Diabetes, Goiânia, Goiás

Quanta Diagnóstico e Terapia, Curitiba, Paraná

Instituto da Crianca com Diabetes, Porto Alegre, Rio Grande Do Sul

Centro de Pesquisa Sao Lucas, Campinas, São Paulo

CPCLIN, Sao Paulo, São Paulo

IBPClin - Instituto Brasil de Pesquisa Clínica, Rio de Janeiro, Not set

CEPIC - Centro Paulista de Investigação Clínica, São Paulo, Not set

C-health Research, Calgary, Alberta

TLC Diabetes and Endocrinology, Surrey, British Columbia

Care Access - Cape Breton, Sydney, Nova Scotia

Centricity Research Ottawa LMC Endocrinology, Ottawa, Ontario

Endocrinologie Oasis, Montréal, Quebec

Centre de Recherche Saint-Louis, Sherbrooke, Quebec

INTENDIA klinika s.r.o., Chrudim III, Chrudim

MUDr. Tomas Edelsberger, Krnov, Moravskoslezský Kraj

AIDIN VK s.r.o., Hranice, Olomoucký Kraj

Milan Kvapil s.r.o., Diabetologicka ambulance, Praha, Praha 4

ResTrial s.r.o., Praha, Praha 8

Diabetologicke centrum s.r.o., Olomouc, Not set

Hôpital de la Conception, Marseille, Bouches-du-Rhône

Hôtel-Dieu du Creusot - site Harfleur, Le Creusot, Bourgogne

CHU Rangueil, Toulouse cedex 9, Haute-Garonne

Centre Hospitalier Universitaire - Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Bois-Guillaume, Haute-Normandie

Centre Hospitalier Universitaire de Grenoble, Grenoble, Isère

Groupe Hospitalier Mutualiste Les Portes du Sud, Vénissieux, Rhône-Alpes

Assistance Publique Hôpitaux de Paris - Groupe Hospitalier 10e - Hôpital Lariboisière, Paris, Not set

Centre Hospitalier Sud Francilien, Corbeil-Essonnes, Île-de-France

Iatriko Paleou Falirou Medical Center, Paleo Faliro, Attikí (Region)

Athens Medical Center, Athens, Attikí

Ippokrateio General Hospital of Thessaloniki, Thessaloniki, Kentrikí Makedonía

Euromedica General Clinic of Thessaloniki, Thessaloniki, Thessaloníki

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal

Unidad de Investigaci�n Cl�nica Cardiometabolica de Occidente, Guadalajara, Jalisco

Private Practice - Dr. Arechavaleta Granell Maria del Rosario, Guadalajara, Jalisco

Unidad de Investigación Clínica y Atención Médica HEPA S.C., Guadalajara, Jalisco

CEINV Salud, Monterrey, Nuevo León

Clínica García Flores SC, Monterrey, Nuevo León

Medsal Centro Médico, Tampico, Tamaulipas

Enclifar Ensayos Clínicos Farmacológicos Sc, Chihuahua, Not set

Consultorio Médico de Endocrinología y Pediatría, Puebla, Not set

Mariodiab Clinic, Brasov, Brașov

Sanamed Hospital, Bucharest, București

Rinart Diab SRL, Targoviste, Dâmbovița

Centrul medical DiabNutriMed, Bucharest, Ilfov

CMI DNBM Dr. Pop Lavinia, Baia Mare, Maramureș

Diabet Med, București, Not set

Diamed Obesity, Galați, Not set

Centrul Medical Consultmed, Iași, Not set

Hospital Germans Trias i Pujol, Badalona, Barcelona [Barcelona]

Hospital Clínic de Barcelona, Barcelona, Catalunya [Cataluña]

Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De

Hospital Infanta Cristina, Badajoz, Not set

Hospital Universitario Virgen Del Rocio, Sevilla, Not set

Conditions: Type 1 Diabetes, Obesity, Overweight

Learn More ›

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

NCT05784428

Recruiting

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs. However, SABR treatment requires increased planning, treatment time, cost and potential for higher toxicity due to the higher dose. The purpose of this study is to compare single fraction (SF) SABR vs. multiple fraction (MF) SABR in regards to toxicities, progression-free survival, qual... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: BC Cancer, Kelowna, British Columbia +4 locations

Conditions: Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life

Learn More ›

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595

Recruiting

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama +52 locations

O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama

University of Southern California, Los Angeles, California

University of California, Los Angeles UCLA, Los Angeles, California

Georgetown University Hospital, Washington, District of Columbia

H Lee Moffitt Cancer Center, Tampa, Florida

University of Maryland School of Medicine, Baltimore, Maryland

University of Michigan Health System, Ann Arbor, Michigan

Start Midwest, Grand Rapids, Michigan

Hattiesburg Clinic, Hattiesburg, Mississippi

NYU Langone Long Island Clinical Research Associates, New York, New York

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, New York

Stephenson Cancer Center, Oklahoma City, Oklahoma

Vanderbilt Ingram Cancer Center, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

Institut Jules Bordet, Anderlecht, Not set

Cliniques Universitaires Saint Luc, Bruxelles, Not set

UZ Antwerpen, Edegem, Not set

Universitair Ziekenhuis Gasthuisberg, Leuven, Not set

BC Cancer Agency - Vancouver BC, Vancouver, British Columbia

The Ottawa Hospital Cancer Centre, Ottawa, Ontario

Princess Margaret Cancer Centre University Health Network, Toronto, Ontario

The Second Hospital To Dalian Medical University, Da Lian Shi, Not set

Sun Yat-sen University - The Sixth Affiliated Hospital Guangdong Gastrointestinal Hospital, Guangzhou, Not set

The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Not set

Hubei province tumor hospital, Wu Han Shi, Not set

Asklepios Klinik Altona, Hamburg, Not set

Ludwig-Maximilians-Universitaet Muenchen, Munich, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

A O Ospedale Niguarda Ca Granda, Milano, Not set

Azienda Ospedaliero Universitaria Pisana, Pisa, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Not set

University Malaya Medical Centre, Kuala Lumpur, Not set

Hospital Umum Sarawak, Kuching, Not set

Beacon Hospital Sdn Bhd, Petaling Jaya, Not set

Ad Vance Medical Research, Ponce, Not set

Pan American Center for Oncology Trials LLC, Rio Piedras, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Ramon Y Cajal, Madrid, Not set

Hosp Univ Fund Jimenez Diaz, Madrid, Not set

Hosp Univ Hm Sanchinarro, Madrid, Not set

Hosp. Univ. Marques de Valdecilla, Santander, Not set

Hosp. Clinico Univ. de Valencia, Valencia, Not set

Changhua Christian Hospital, Changhua, Not set

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set

Chi Mei Medical Center Liu Ying, Liou Ying Township, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Linkou Chang Gung Memorial Hospital, Taoyuan, Not set

Conditions: Advanced or Metastatic Colorectal Cancer

Learn More ›

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06603077

Recruiting

The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: Clinical Site 1022, Scottsdale, Arizona +71 locations

Clinical Site 1022, Scottsdale, Arizona

Clinical Site 1026, Tucson, Arizona

Clinical Site 1032, Northridge, California

Clinical Site 1019, Pomona, California

Clinical Site 1009, Sacramento, California

Clinical Site 1011, Washington, District of Columbia

Clinical Site 1029, Boca Raton, Florida

Clinical Site 1002, Coral Gables, Florida

Clinical Site 1015, Maitland, Florida

Clinical Site 1027, North Miami Beach, Florida

Clinical Site 1013, Tampa, Florida

Clinical Site 1008, Savannah, Georgia

Clinical Site 1014, Chicago, Illinois

Clinical Site 1028, West Lafayette, Indiana

Clinical Site 1031, Bowling Green, Kentucky

Clinical Site 1024, Murray, Kentucky

Clinical Site 1001, Boston, Massachusetts

Clinical Site 1007, Ft. Gratiot, Michigan

Clinical Site 1041, Oakland, Michigan

Clinical Site 1003, Portsmouth, New Hampshire

Clinical Site 1023, Bronx, New York

Clinical Site 1036, Brooklyn, New York

Clinical Site 1016, New York, New York

Clinical Site 1020, Cincinnati, Ohio

Clinical Site 1010, Cleveland, Ohio

Clinical Site 1017, Dublin, Ohio

Clinical Site 1004, Philadelphia, Pennsylvania

Clinical Site 1018, Johnston, Rhode Island

Clinical Site 1005, Greenville, South Carolina

Clinical Site 1012, Arlington, Texas

Clinical Site 1203, Darlinghurst, New South Wales

Clinical Site 1201, Westmead, New South Wales

Clinical Site 1202, Carlton, Victoria

Clinical Site 1303, Sofia, Sofia-Grad

Clinical Site 1302, Lovech, Not set

Clinical Site 1301, Pleven, Not set

Clinical Site 1304, Stara Zagora, Not set

Clinical Site 1105, Edmonton, Alberta

Clinical Site 1108, Edmonton, Alberta

Clinical Site 1103, Barrie, Ontario

Clinical Site 1104, Hamilton, Ontario

Clinical Site 1107, London, Ontario

Clinical Site 1106, Toronto, Ontario

Clinical Site 1101, Saskatoon, Saskatchewan

Clinical Site 1401, Praha 10, Prague

Clinical Site 1402, Praha 5, Prague

Clinical Site 1503, Antony, Hauts-de-Seine

Clinical Site 1504, Paris, Ile-de-France

Clinical Site 1505, Amiens, Picardie

Clinical Site 1502, Lyon, Rhône

Clinical Site 1501, Rouen Cedex, Seine-Maritime

Clinical Site 1606, Erlangen, Bayern

Clinical Site 1604, Frankfurt, Hessen

Clinical Site 1601, Bochum, Nordrhein-Westfalen

Clinical Site 1602, Muenster, Nordrhein-Westfalen

Clinical Site 1901, Torrette, Ancona

Clinical Site 1903, Rozzano, Milano

Clinical Site 1908, Milano, Not set

Clinical Site 1907, Roma, Not set

Clinical Site 1904, Roma, Not set

Clinical Site 1702, Wroclaw, Kujawsko-Pomorskie

Clinical Site 1703, Bialystok, Podlaskie

Clinical Site 1701, Warszawa, Pomorskie

Clinical Site 1705, Warszawa, Pomorskie

Clinical Site 1704, Ossy, Slaskie

Clinical Site 2202, Svidnik, Presovsky Kraj

Clinical Site 2201, Trnava, Trnavsky kraj

Clinical Site 1801, Manises, Valencia

Clinical Site 1802, Granada, Not set

Clinical Site 1803, Madrid, Not set

Clinical Site 1804, Sevilla, Not set

Clinical Site 2001, Gaziantep, Not set

Conditions: Hidradenitis Suppurativa

Learn More ›